8.1 Prescription Processing, Verification, and Drug Therapy Problem Management

8.1 Prescription Processing, Verification, and Drug Therapy Problem Management

Exam Focus: Evaluating prescription legality, executing technical and clinical verification, identifying and resolving Drug Therapy Problems (DTPs) using the Cipolle framework, and implementing safety strategies for high-risk medications are core competencies heavily tested on the PEBC Evaluating Examination.

---

Canadian Legal and Regulatory Framework for Prescriptions

In Canada, the authority to prescribe, dispense, and distribute pharmaceuticals is governed by an interlocking framework of federal statutes—primarily the Food and Drugs Act (FDA) and the Controlled Drugs and Substances Act (CDSA)—and provincial/territorial pharmacy acts and regulations.

+-------------------------------------------------------------------------+
|                 CANADIAN PRESCRIPTION REGULATORY PYRAMID                |
+-------------------------------------------------------------------------+
|  FEDERAL STATUTES: Food and Drugs Act (FDA) & Regulations (FDR)         |
|  - Establishes Prescription Drug List (PDL) and manufacturing standards |
|                                                                         |
|  FEDERAL CONTROLLED STATUTES: CDSA & Associated Regulations             |
|  - Narcotic Control Regulations (NCR)                                   |
|  - Benzodiazepines and Other Targeted Substances Regulations (BOTSR)    |
|  - Food and Drug Regulations - Part G (Controlled Drugs)               |
|                                                                         |
|  PROVINCIAL / TERRITORIAL STATUTES & PRA REGULATIONS                   |
|  - Pharmacy Acts, Drug Schedules (NAPRA Schedules I, II, III, Unscheduled)|
|  - Pharmacist Scope of Practice, Minor Ailments, Prescribing/Adapting   |
|  - Professional Practice Policies and Operational Standards             |
+-------------------------------------------------------------------------+

Mandatory Legal Elements of a Valid Prescription

A valid prescription in Canadian practice must contain specific statutory elements before it can be legally processed and dispensed:

1. Patient Identifiers: Full legal first and last name, current residential address, and unique health identifier (such as provincial health card number) or date of birth.
2. Prescriber Identifiers: Full name, practice address, contact telephone number, professional license or registration number (e.g., CPSO, CPBC, CNO, or provincial PRAC ID), and handwritten or certified cryptographic electronic signature conforming to provincial standards.
3. Date of Issuance: The exact calendar date on which the prescription was authored and authorized by the prescriber.
4. Medication Specifications:
   • Drug name (generic chemical entity or specific proprietary brand name).
   • Strength or concentration (e.g., 25 mg, 5 mg/mL; trailing zeros must be avoided, such as 5 mg rather than 5.0 mg, and leading zeros must be included, such as 0.5 mg rather than .5 mg).
   • Dosage form (e.g., tablet, extended-release capsule, oral suspension, transdermal patch).
   • Precise directions for use (Signatura / Sig) specifying dose, route, frequency, and duration or specific indication for PRN (as-needed) use.
   • Total quantity to be dispensed (expressed numerically and, for controlled/narcotic substances, often recommended in written word format to prevent alteration).
   • Refill authorizations: Number of authorized refills or specified part-fill intervals. For narcotics, the term "refill" is legally void; authorized repeat dispensings must be designated as "part-fills" specifying exact quantity and time intervals.

---

The Two-Step Dispensing Verification Model

To ensure medication safety, modern Canadian pharmacy practice separates the dispensing workflow into two distinct, rigorous verification stages: Technical Verification and Clinical Verification.

+-------------------------------------------------------------------------+
|                   TWO-STEP DISPENSING VERIFICATION MODEL                |
+-------------------------------------------------------------------------+
|                                                                         |
|  [STAGE 1: TECHNICAL VERIFICATION]                                     |
|  Performed by: Registered Pharmacy Technician (RPhT) or Pharmacist      |
|  - Right Patient, Right Drug, Right Strength, Right Dosage Form         |
|  - Drug Identification Number (DIN) verification & Barcode scanning     |
|  - Right Quantity, Calculated Days Supply, Correct Auxiliary Labels     |
|  - Packaging integrity and physical container inspection                |
|                                |                                        |
|                                v                                        |
|  [STAGE 2: CLINICAL VERIFICATION]                                      |
|  Performed by: Licensed Pharmacist (Independent Cognitive Function)    |
|  - Indication appropriateness and evidence-based guideline alignment    |
|  - Dose, frequency, and duration verification (organ function, age, wt)|
|  - Contraindications, allergies, and cross-reactivity assessment       |
|  - Drug-Drug, Drug-Disease, Drug-Food, and Drug-Lab Interactions       |
|  - Therapeutic duplication and high-risk safety checks                 |
|  - Patient-specific adherence, lab monitoring, and follow-up plan       |
|                                                                         |
+-------------------------------------------------------------------------+

Technical Verification (Product-Focused)

Technical verification confirms that the physical product packaged matches the entered prescription order exactly. Registered Pharmacy Technicians (RPhTs) in Canada are autonomous, regulated healthcare professionals legally authorized to perform independent technical verification:

• Drug Identification Number (DIN): Cross-referencing the 8-digit DIN on the stock bottle with the generated dispensing label.
• Physical Accuracy: Ensuring correct count, volume, packaging container (e.g., child-resistant closure or easy-open vial upon documented patient request), and amber light protection.
• Auxiliary Warning Labels: Affixing mandatory auxiliary labels (e.g., "Take with food", "Avoid sunlight", "Do not crush", "Refrigerate - Do not freeze", "Shake well").

Clinical Verification (Patient-Focused)

Clinical verification is the exclusive, non-delegable cognitive responsibility of the Pharmacist. It evaluates whether the pharmacotherapeutic regimen is safe, indicated, effective, and optimal for the specific patient.

---

The Cipolle, Morley, and Strand Drug Therapy Problem (DTP) Framework

A Drug Therapy Problem (DTP) is any undesirable event experienced by a patient that involves, or is suspected to involve, drug therapy, and that interferes with achieving the desired goals of therapy. The PEBC evaluates candidate competence in categorizing DTPs using the standardized framework developed by Cipolle, Morley, and Strand.

---

Systematic DTP Resolution and Clinical Communication

When a DTP is identified, the pharmacist must formulate a structured, evidence-based care plan using the Pharmacist's Patient Care Process (PPCP):

1. Assess: Analyze subjective symptoms, objective laboratory data (eGFR, electrolytes, blood glucose, INR), past medical history, and drug interaction databases.
2. Formulate Recommendation: Determine optimal alternatives, dose adjustments, monitoring parameters, and clinical timelines.
3. Communicate with Prescriber (SBAR Format):
   • Situation: State the immediate reason for communication and patient identity.
   • Background: Provide relevant clinical context (diagnosis, current regimen, organ function, lab values).
   • Assessment: Clearly articulate the specific DTP and clinical risk (e.g., acute renal failure, hyperkalemia, toxicity).
   • Recommendation: Propose a clear, actionable, evidence-based therapeutic alternative (specific drug, dose, route, frequency, and monitoring plan).
4. Document (SOAP Format): Document the intervention in the patient's health record:
   • S (Subjective): Patient-reported symptoms, adherence barriers, complaints.
   • O (Objective): Vital signs, lab values, diagnostic imaging, current medication list.
   • A (Assessment): Comprehensive pharmacotherapeutic evaluation and explicit DTP statement.
   • P (Plan): Drug therapy modifications, patient counseling points, monitoring parameters, and scheduled follow-up.

+-------------------------------------------------------------------------+
|                    SBAR INTERCOMMUNICATION STRUCTURE                    |
+-------------------------------------------------------------------------+
|  S - Situation:      "Dr. Smith, this is Pharmacist Alex calling about  |
|                      Jane Doe regarding her new methotrexate order."    |
|                                                                         |
|  B - Background:     "Jane is a 62-year-old female with rheumatoid      |
|                      arthritis initiated on methotrexate today."        |
|                                                                         |
|  A - Assessment:     "The prescription is written for 15 mg DAILY.      |
|                      Daily dosing of oral methotrexate causes fatal     |
|                      myelosuppression and mucositis; standard dosing   |
|                      for RA is ONCE WEEKLY."                            |
|                                                                         |
|  R - Recommendation: "I recommend modifying the order to 15 mg PO ONCE  |
|                      WEEKLY on Mondays, co-prescribing Folic Acid 5 mg  |
|                      weekly, and ordering baseline CBC and LFTs."       |
+-------------------------------------------------------------------------+

---

High-Risk Medication Safety Strategies

The Institute for Safe Medication Practices (ISMP) Canada identifies specific high-alert medications that bear a heightened risk of causing significant patient harm when used in error:

Critical Medication Safety Pitfalls

• Methotrexate Dosing Errors: Oral methotrexate for non-oncologic indications (e.g., rheumatoid arthritis, psoriasis) must be administered strictly as a single weekly dose. Dispensing daily methotrexate represents a catastrophic error leading to fatal pancytopenia, gastrointestinal ulceration, and sepsis. Verification safeguards include requiring a weekly administration day on the label, packaging in unit-dose blisters, and hard-stop computer alerts.
• Look-Alike / Sound-Alike (LASA) Confusions: Examples include hydralazine vs. hydroxyzine, celecoxib vs. Celexa (citalopram), hydroxychloroquine vs. hydrochloroquine, and methadone vs. methylphenidate. Mitigated via Tall Man lettering (e.g., hydrOXYzine vs. hydrALAZINE) and indication-based prescribing.
• Direct Oral Anticoagulants (DOACs): Dosing must be adjusted strictly based on renal function, body weight, age, and drug interactions (e.g., apixaban 2.5 mg BID if at least 2 of: age $\ge 80$ years, weight $\le 60$ kg, serum creatinine $\ge 133\ \mu\text{mol/L}$). Concomitant use with strong dual P-gp and CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) or inducers (e.g., rifampin, carbamazepine) requires dosage adjustment or avoidance.
• Potassium Chloride and Concentrated Electrolytes: Concentrated IV potassium chloride vials must never be stored in patient care areas and require independent double-checks prior to infusion to prevent lethal cardiac arrest.